# SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer

> **NCT06859775** · PHASE1,PHASE2 · RECRUITING · sponsor: **Suzhou Suncadia Biopharmaceuticals Co., Ltd.** · enrollment: 100 (estimated)

## Conditions studied

- Recurrent or Metastatic Cervical Cancer

## Interventions

- **DRUG:** SHR-A1811
- **DRUG:** Adebelimab injection
- **DRUG:** Bevacizumab injection
- **DRUG:** SHR-8068
- **DRUG:** Cisplatin injection
- **DRUG:** Carboplatin injection

## Key facts

- **NCT ID:** NCT06859775
- **Lead sponsor:** Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-25
- **Primary completion:** 2026-10
- **Final completion:** 2027-01
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06859775

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06859775, "SHR-A1811 Combination Regimen for the Treatment of Recurrent or Metastatic Cervical Cancer". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06859775. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*